Pharming Group N.V.

ENXTAM:PHARM Stok Raporu

Piyasa değeri: €513.9m

Pharming Group Yönetim

Yönetim kriter kontrolleri 2/4

Pharming Group CEO'su Simon de Vries, Nov2008 tarihinde atandı, in görev süresi 16.08 yıldır. in toplam yıllık tazminatı $ 2.81M olup, şirket hissesi ve opsiyonları dahil olmak üzere 24% maaş ve 76% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.13% ine doğrudan sahiptir ve bu hisseler € 10.96M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 3.7 yıldır.

Anahtar bilgiler

Simon de Vries

İcra Kurulu Başkanı

US$2.8m

Toplam tazminat

CEO maaş yüzdesi24.0%
CEO görev süresi16yrs
CEO sahipliği2.1%
Yönetim ortalama görev süresi3.8yrs
Yönetim Kurulu ortalama görev süresi3.7yrs

Son yönetim güncellemeleri

Recent updates

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14
Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Nov 11
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 23
Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Jun 20
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Mar 16
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 17
Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Dec 08
We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Aug 05
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

Mar 21
Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Mar 19
These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Feb 20
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Oct 29
Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Jun 03
Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

May 12
Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

CEO Tazminat Analizi

Simon de Vries'un ücretlendirmesi Pharming Group'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$18m

Jun 30 2024n/an/a

-US$13m

Mar 31 2024n/an/a

-US$11m

Dec 31 2023US$3mUS$673k

-US$11m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

-US$16m

Mar 31 2023n/an/a

-US$2m

Dec 31 2022US$2mUS$636k

US$14m

Sep 30 2022n/an/a

US$30m

Jun 30 2022n/an/a

US$21m

Mar 31 2022n/an/a

US$11m

Dec 31 2021US$3mUS$681k

US$16m

Sep 30 2021n/an/a

US$22m

Jun 30 2021n/an/a

US$31m

Mar 31 2021n/an/a

US$37m

Dec 31 2020US$3mUS$614k

US$38m

Sep 30 2020n/an/a

US$44m

Jun 30 2020n/an/a

US$46m

Mar 31 2020n/an/a

US$42m

Jan 01 2020n/an/a

US$41m

Sep 30 2019n/an/a

US$38m

Jun 30 2019n/an/a

US$34m

Mar 31 2019n/an/a

US$29m

Dec 31 2018US$2mUS$579k

US$29m

Sep 30 2018n/an/a

-US$29m

Jun 30 2018n/an/a

-US$44m

Mar 31 2018n/an/a

-US$80m

Dec 31 2017US$2mUS$537k

-US$91m

Tazminat ve Piyasa: Simon 'nin toplam tazminatı ($USD 2.81M ), Dutch pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 874.94K ).

Tazminat ve Kazançlar: Simon şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Simon de Vries (65 yo)

16yrs

Görev süresi

US$2,809,000

Tazminat

Dr. Sijmen De Vries, also known as Simon, M. D., M. B.A., has been the Chief Executive Officer of Pharming Group N. V. since November 03, 2008 and also serves as its Executive Director since October 13, 20...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Sijmen de Vries
President16yrsUS$2.81m2.13%
€ 11.0m
Jeroen Wakkerman
Chief Financial Officer4yrsVeri yok0.064%
€ 326.3k
Mireille Sanders
Chief Operations Officer5.3yrsVeri yok0.12%
€ 605.3k
Susanne Embleton
Investor Relations Managerno dataVeri yokVeri yok
Ruud Van Outersterp
Chief Ethics & Compliance Officer3.5yrsVeri yok0.024%
€ 125.1k
Anurag Relan
Chief Medical Officer3.4yrsVeri yok0.027%
€ 139.6k
Stephen Toor
Chief Commercial Officer & GM Americas7.8yrsVeri yok0.028%
€ 142.2k
Alexander Breidenbach
Chief Business Officer1.2yrsVeri yok0.0096%
€ 49.5k
Bruno M. Giannetti
Consultant3.4yrsVeri yokVeri yok

3.8yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: PHARM 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Sijmen de Vries
President16.1yrsUS$2.81m2.13%
€ 11.0m
Leonard Kruimer
Independent Non-Executive Director3.5yrsUS$90.00k0.018%
€ 91.8k
Mark Pykett
Independent Non-Executive Director3.9yrsUS$87.00k0.022%
€ 110.6k
Deborah Jorn
Independent Non-Executive Vice-Chairperson5.5yrsUS$87.00k0.024%
€ 122.5k
Steven Baert
Independent Non-Executive Director3.5yrsUS$90.00k0.018%
€ 91.8k
Barbara Yanni
Independent Non-Executive Director3.9yrsUS$94.00k0.022%
€ 110.6k
Richard Peters
Non-Executive Chairman of Board1.2yrsUS$46.00k0.0093%
€ 47.6k
Jabine van der Meijs
Independent Non-Executive Director3.5yrsUS$94.00k0.018%
€ 91.8k

3.7yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PHARM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.7 yıldır).